Exclusive Summary

• First-in-class Mechanism & Superior Safety: As the world's first highly selective partial agonist targeting the GABA-A receptor α1 subunit, it guarantees high hypnotic efficacy (fast onset + prolonged sleep) while avoiding daytime hangover, cognitive impairment, and addiction risks common in traditional sleeping pills.
• Unique FMO Metabolic Pathway (Minimal DDI Risk): Unlike most competitors metabolized by CYP450, Dimdazenil is exclusively metabolized by the FMO enzyme, resulting in minimal drug-drug interactions. It is the drug of choice for elderly patients and those with comorbidities requiring polypharmacy.
• Optimal Pharmacokinetics (PK): Induces sleep rapidly with a peak time of 1 hour, and effectively maintains physiological sleep with a half-life of ~4 hours (no drug accumulation). Furthermore, no dose adjustment is needed for patients with mild to moderate liver or kidney impairment.
• High Certainty for Out-licensing & Global Access: It is a New Chemical Entity (NCE) with 100% global development and commercialization rights available. Approved in China (2023) ensuring therapeutic proof-of-concept, with solid clinical progress in the US (Phase II) and EU (Phase I), backed by an EU GMP-certified manufacturing site.

Asset Materials

Contact Us for Full Materials